These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32367340)

  • 21. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial.
    Emami H; Vucic E; Subramanian S; Abdelbaky A; Fayad ZA; Du S; Roth E; Ballantyne CM; Mohler ER; Farkouh ME; Kim J; Farmer M; Li L; Ehlgen A; Langenickel TH; Velasquez L; Hayes W; Tawakol A
    Atherosclerosis; 2015 Jun; 240(2):490-6. PubMed ID: 25913664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects.
    Min KL; Park MS; Jung J; Chang MJ; Kim CO
    Clin Ther; 2017 Sep; 39(9):1799-1810. PubMed ID: 28803122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial.
    Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Ono T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    J Cardiol; 2015 Oct; 66(4):353-8. PubMed ID: 25577723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study: study protocol for a randomized controlled trial.
    Fonseca FAH; Izar MC; Maugeri IML; Berwanger O; Damiani LP; Pinto IM; Szarf G; França CN; Bianco HT; Moreira FT; Caixeta A; Alves CMR; Soriano Lopes A; Klassen A; Tavares MFM; Fonseca HA; Carvalho ACC;
    Trials; 2017 Dec; 18(1):601. PubMed ID: 29258572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
    Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Water- and Lipid-Soluble Statins on Nonculprit Lesions in Patients with Acute Coronary Syndrome.
    Ishikawa Y; Itoh T; Satoh M; Fusazaki T; Sugawara S; Nakajima S; Nakamura M; Morino Y
    Int Heart J; 2018 Jan; 59(1):27-34. PubMed ID: 29279527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
    Li L; Zhang M; Su F; Li Y; Shen Y; Shen J; Zhang D
    Lipids Health Dis; 2015 Feb; 14():10. PubMed ID: 25879728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
    Lancellotti P; Pierard LA; Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ezetimibe-rosuvastatin fixed-dose combination (Myrosor®)].
    Wallemacq C; Scheen AJ
    Rev Med Liege; 2020 Apr; 75(4):260-264. PubMed ID: 32267116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.
    Kim BK; Hong SJ; Lee YJ; Hong SJ; Yun KH; Hong BK; Heo JH; Rha SW; Cho YH; Lee SJ; Ahn CM; Kim JS; Ko YG; Choi D; Jang Y; Hong MK;
    Lancet; 2022 Jul; 400(10349):380-390. PubMed ID: 35863366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin.
    Otake H; Sugizaki Y; Toba T; Nagano Y; Tsukiyama Y; Yanaka KI; Yamamoto H; Nagasawa A; Onishi H; Takeshige R; Nakano S; Matsuoka Y; Tanimura K; Kawamori H; Shinke T; Hirata KI
    J Cardiol; 2019 Mar; 73(3):228-232. PubMed ID: 30579806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural history of atherosclerotic disease progression as assessed by (18)F-FDG PET/CT.
    Hetterich H; Rominger A; Walter L; Habs M; Volpers S; Hacker M; Reiser MF; Bartenstein P; Saam T
    Int J Cardiovasc Imaging; 2016 Jan; 32(1):49-59. PubMed ID: 25898891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.
    Averna M; Missault L; Vaverkova H; Farnier M; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Taggart W; Brudi P
    Diab Vasc Dis Res; 2011 Oct; 8(4):262-70. PubMed ID: 21859750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.
    Saeedi R; Johns K; Frohlich J; Bennett MT; Bondy G
    Lipids Health Dis; 2015 Jun; 14():57. PubMed ID: 26087958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: A 6-year population-based cohort study.
    Lin Wu FL; Wang J; Ho W; Chou CH; Wu YJ; Choo DW; Wang YW; Chen PY; Chien KL; Lin ZF
    Int J Cardiol; 2017 Apr; 233():43-51. PubMed ID: 28190615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
    Altunkeser BB; Tuncez A; Ozturk B; Tezcan H; Ates MS; Yilmaz C; Yalcin MU; Aygul N; Demir K
    Coron Artery Dis; 2019 Jun; 30(4):285-290. PubMed ID: 30741744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects
.
    Kang WY; Seong SJ; Ohk B; Gwon MR; Kim BK; Na S; Kim HJ; Yoon YR; Lee HW
    Int J Clin Pharmacol Ther; 2018 Jan; 56(1):43-52. PubMed ID: 29162214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
    Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C
    Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial.
    Fujisue K; Nagamatsu S; Shimomura H; Yamashita T; Nakao K; Nakamura S; Ishihara M; Matsui K; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Sakamoto K; Izumiya Y; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
    Int J Cardiol; 2018 Oct; 268():23-26. PubMed ID: 29925472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial.
    Tsujita K; Yamanaga K; Komura N; Sakamoto K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    Eur J Prev Cardiol; 2016 Sep; 23(14):1524-8. PubMed ID: 27296705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.